Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Andreoli S. 1, Bachini L. 1, Pedrinazzi C. 1, Dal Canto L. 2, Cervadoro G. 1
1 Scuola di Specializzazione in Dermatologia e Venereologia Università degli Studi di Pisa, Pisa
2 U.O. Farmacia Ospedale Santa Chiara, Pisa
Aim. Cidofovir is an antiviral drug that has been approved for the treatment of Cytomegalovirus retinitis in AIDS patients. It presents a wide antiviral spectrum against Herpesvirus (HSV 1-2, VZV, CMV, EBV), Adenovirus, Poxvirus e Papillomavirus. Its mechanism of action consists in the selective block of viral DNA’s synthesis. In our study we evaluated the efficacy of Cidofovir by endovenous infusion in the treatment of anogenital warts.
Methods. The 6 patients enrolled in our study had already tried several chemical and physical therapies without long-lasting results. Each of them presented recurrence of symptoms after few months from treatment. We followed the same therapeutic protocol used for the CMV retinitis: for each therapy session, 4 infusions of Cidofovir at a dosage of 5 mg/kg.
Results. In 1 patient we needed just 1 cycle of therapy to obtain complete resolution of the lesions; in the other 4 cases a 2nd application was necessary to achieve the same result. Only in 1 patient we observe the onset of hypospermia, but it spontaneously relapsed after 2 months from end of therapy. We didn’t observed any other collateral effect that can occur during treatment with endovenous Cidofovir (neutropenia, nephrotoxicity). After 1 year from treatment we didn’t observe any recurrence of lesions in these patients.
Conclusion. We presented this study to underline the efficacy of Cidofovir used by endovenous infusion in the therapy of anogenital warts HPV related.